Media Articles Related to Brimonidine ( Ophthalmic)
Data demonstrates long term effectiveness and safety of telescope implant for macular degeneration in patients 65 years and older
Source: Eye Health / Blindness News From Medical News Today [2015.06.30]
VisionCare Ophthalmic Technologies, Inc. a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), has announced the publication of "Long-Term...
Published Studies Related to Brimonidine ( Ophthalmic)
Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus
bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or
ocular hypertension: a 12-week randomised controlled trial. 
hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of
the OPUS-1 phase 3 study. 
PARTICIPANTS: A total of 588 adult subjects with dry eye disease... CONCLUSIONS: Lifitegrast ophthalmic solution 5.0% significantly reduced corneal
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple
for multiple sclerosis (MS)... CONCLUSIONS: Fingolimod 0.5 mg is associated with a low incidence of ME in MS
Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic
conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical
Allergic conjunctivitis (AC) affects an estimated 20% of the population in the
Western world, with a large fraction suffering due to seasonal or perennial
allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, a
dual-acting histamine (H(1)) receptor antagonist and mast cell stabilizer, is
indicated for itching associated with AC...
Progesterone increases resistance of ophthalmic and central retinal arteries in
climacteric women. 
compared to placebo, using transorbital ultrasound with Doppler velocimetry... CONCLUSIONS: Our results demonstrate the existence of a progestogenic
Clinical Trials Related to Brimonidine ( Ophthalmic)
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Completed]
This study evaluates the safety and efficacy of brimonidine 0. 2%/timolol 0. 5% fixed
combination ophthalmic solution compared with concurrent brimonidine 0. 2% and timolol
Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs [Completed]
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and
brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy
(bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% [Recruiting]
Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension [Recruiting]
A multi-center, double-masked, randomized parallel group efficacy and safety study of
brinzolamide 1% /brimonidine 0. 2% fixed combination compared to brinzolamide 1% and to
brimonidine 0. 2% in patients with open-angle glaucoma or ocular hypertension.
Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension [Recruiting]
This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed
combination compared with brimonidine tartrate and timolol in patients with glaucoma or
ocular hypertension who do not respond well to topical beta blockers.